Cardiothyreosis: Risk Factors and Clinical Profile
- 1 Department of Internal Medicine, Abass Ndao Hospital Center, Cheikh Anta Diop University, Dakar, Senegal
- 2 Department of Internal Medicine, Abass Ndao Hospital Center, Cheikh Anta Diop University, Dakar, Senegal
- 3 Department of Preventive Medicine and Public Health, Cheikh Anta Diop University, Dakar, Senegal
- 4 Department of Internal Medicine, Abass Ndao Hospital Center, Cheikh Anta Diop University, Dakar, Senegal
- 5 Cardiology Department, Aristide LeDantec Hospital Center, Cheikh Anta Diop University, Dakar, Senegal
- 6 Department of Internal Medicine, Abass Ndao Hospital Center, Cheikh Anta Diop University, Dakar, Senegal
- 7 Department of Internal Medicine, Abass Ndao Hospital Center, Cheikh Anta Diop University, Dakar, Senegal
- 8 Department of Internal Medicine, Abass Ndao Hospital Center, Cheikh Anta Diop University, Dakar, Senegal
- 9 Department of Internal Medicine, Abass Ndao Hospital Center, Cheikh Anta Diop University, Dakar, Senegal
- 10 Department of Internal Medicine, Abass Ndao Hospital Center, Cheikh Anta Diop University, Dakar, Senegal
Abstract
Introduction: The diagnosis of cardiothyreosis is based on the presence of the association of thyrotoxicosis and various cardiovascular disorders such as heart failure, coronary artery disease, rhythm or conduction disorders. Data are limited on this entity in Africa which a frequency of 10% to 33% among hyperthyroidism. We aimed to evaluate these risk factors and describe its diagnostic features in Abass Ndao Hospital Center of Dakar. Patients and Methods: It was a descriptive and analytical cross sectional study conducted from 1 January 2010 to 31 December 2014, including all cases of hyperthyroidism with cardiothyreosis. Epidemiological data, cardiovascular risk factors and characteristics of cardiothyreosis were evaluated. Results: 150 cases of cardiothyreosis were collected with a prevalence of 9.8% among 1517 hyperthyroidism. Mean age was 42.6 ± 9 years and sex ratio 0.33. It was a Graves’ disease in 82.2% of cases. Time limit of cardiothyreosis appearance was 27 ± 41 months and cardiothyreosis was inaugural in 46.6%. Electrocardiogram showed an arrhythmia (38.7%), coronary insufficiency (8%). On echocardiography assessment, impairment of left ventricular ejection fraction (LVEF) was found in 18.5%. Of these, it was 34.7% of arrhythmia, 8.6% of coronary insufficiency and 65.2% of heart failure. Among patients with pulmonary artery hypertension (PAH) (57.3%), there were a rhythm disorder (38%), coronary insufficiency (5.6%) and heart failure (78.8%). Female gender was the only one at risk of arrhythmia (p = 0.01) and impaired of left ventricular ejection fraction (p = 0.007). Existence of a free T4 > 50 pmol/L (p = 0.05) were only at risk of developing pulmonary artery hypertension. Conclusion: Cardiothyreosis is a significant complication. These discovery methods call for more early diagnosis and appropriate treatment. Female gender and severity of thyrotoxicosis seem to precipitate the clinical picture. Echocardiography remains an indispensable tool for assessing cardiac consequences.
- Yaméogo, A.A., Yaméogo, N.V., Compaoré, Y.D., Ouédraogo, T.L. and Zabsonré, P. (2012) Cardiothyreosis at the University Hospital of Bobo-Dioulasso, Burkina Faso. The Pan African Medical Journal, 11, 1-7.
- Dahl, P., Danzi, S. and Klein, I. (2008) Thyrotoxic Cardiac Disease. Current Heart Failure Reports, 5, 170-176. https://doi.org/10.1007/s11897-008-0026-9
- Frost, L., Vestergaard, P. and Mosekilde, L. (2004) Hyperthyroidism and Risk of Atrial Fibrillation or Flutter: A Population-Based Study. Archives of Internal Medicine, 164, 1675-1678. https://doi.org/10.1001/archinte.164.15.1675
- Kahaly, G.J. and Dillmann, W.H. (2005) Thyroid Hormone Action in the Heart. Endocrine Reviews, 26, 704-728. https://doi.org/10.1210/er.2003-0033
- Niakara, A., Nébié, L.V.A. and Drabo, Y.J. (2000) Cardiothyreosis: Retrospective Study of 32 Cases in the Cardiology and Internal Medicine Department at Ouagadougou, Burkina Faso (1993-1998). Bulletin de la Société de pathologie exotique, 93, 25-28.
- Wade, B., Tiendrebeogo, A.J. and Charles, D. (1999) Cardiothyreosis: About 16 Senegalese Observations. Medicale d'Afrique Noire, 46, 251-257.
- Diallo, B., Sanogo, K.M., Diakité, S., Diarra, M.B. and Ba, S.S. (2004) The Cardiothyreosis at the G-Spot Hospital. Mali Medical, Tome XIX N°2, 22-27.
- Lorcy, Y. and Klein, M. (2005) Thyroid Dysfunction and Cardiovascular Disease: Encycl. Med. Chir, Cardiology, [11-048-A-10].
- Galiè, N., Torbicki, A., Barst, R., et al. (2004) The Task Force on Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology. ESC guidelines: Guidelines on Diagnosis and Treatment of Pulmonary Arterial Hypertension. European Heart Journal, 25, 2243-2278. https://doi.org/10.1016/j.ehj.2004.09.014
- Oliveros-Ruiz, L., Vallejo, M., Diez Canseco, L.F., Cárdenas, M. and Hermosillo, J.A.G. (2013) Determinants of Thyrotoxic Cardiomyopathy Recovery. BioMed Research International, 2013, Article ID: 452709. https://doi.org/10.1155/2013/452709
- Nkoua, J.L., Mban, B., Bandoho-Mambo, A., Aba, G. and Bouramoue, Ch. (2000) Cardiothyreosis: Frequency, Etiology and Nosology Aspect about 20 Cases. Medicale d'Afrique Noire, 47, 450-454.
- El Hattaoui, M., Charei, N., Mouniri, M. and Diouri, A. (2009) Cardiothyreosis in the Region of Marrakesh: about 36 Cases. Ann Cardiol Angeiol, 58, 135-138. https://doi.org/10.1016/j.ancard.2008.07.006